$VSTM News
Last published 3d ago
- 3d agoVSTMGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - VERASTEM INCEarnings Call TranscriptsAll right, so I'm Michael Schmidt, senior biotech analyst with Guggenheim. It is my great pleasure to welcome the next presenting company here with me. I have Veristem, Jonathan Pachter, CSO, and Tim Wu, head of developm
- 3w agoVSTMVerastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026Business WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and
- 4w agoVSTMVerastem Oncology VS-7375 R&D Update - VERASTEM INCEarnings Call TranscriptsGood morning, everyone. For those that don't know me, I'm Julissa Vianna, the Senior Vice President of Corporate Communications, Investor Relations, and Patient Advocacy. We're really excited to have you here today, and
- 4w agoVSTMVerastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded WarrantsBusiness WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today
- 4w agoVSTMVerastem Oncology Announces Planned Chief Executive Officer Transition and Succession PlanBusiness WireAccomplished biopharmaceutical executive Michael P. Bailey appointed President and CEO to advance Verastem’s commercial business and lead pipeline asset advancement for VS-7375, a potential best-in-class
- 4w agoVSTMVS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)Business WireVS-7375 900 mg QD monotherapy achieved a 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma (PDAC) patient population and a 36% confirmed ORR in 3-4L; responses are durable with a majority of
- 1mo agoVSTMVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to
- 1mo agoVSTMVerastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026Business WireRAMP 201 molecular profiling showed clinically meaningful activity in KRAS wild-type recurrent LGSOC, including ORRs of 22% in patients with NRAS- or BRAF-mutated tumors and 18% in patients with KRAS/NRAS/BRAF triple
- 1mo agoVSTMVerastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian CancerBusiness WireRAMP 201 study supported FDA Accelerated Approval of AVMAPKI FAKZYNJA CO-PACK for treatment of KRAS-mutated recurrent LGSOC following prior systemic therapy Across patients with KRAS wild-type and KRAS-mutated
- 1mo agoONCYRVMDAMGNLLY+1KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034PR NewswireEquity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the...
- 1mo agoVSTMVerastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global MeetingBusiness WireOral presentation of the results from the RAMP 201J study of avutometinib plus defactinib in recurrent LGSOC in Japanese patients New external control arm analysis of avutometinib plus defactinib versus
- 2mo agoVSTMVerastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal CancersBusiness WireInvestor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK
- 2mo agoVSTMVerastem Oncology to Participate in Upcoming September Investor ConferencesBusiness WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate
- 3mo agoVSTMVerastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business UpdatesBusiness WireAVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+
- 3mo agoVSTMVerastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal CancerBusiness WireTARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal cancer A cohort in TARGET-D 203 will also evaluate the
- 3mo agoVSTMVerastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026Business WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and
- 3mo agoVSTMVerastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung CancerBusiness WireTARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer A cohort in TARGET-D 202 will also evaluate VS-7375 in non-small cell lung
- 4mo agoVSTMVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new
- 4mo agoVSTMVS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid TumorsBusiness WireBroad anti-tumor activity observed with VS-7375 across dose levels in multiple solid tumors, including pancreatic, colorectal, and lung cancers Early evidence of anti-tumor activity with either anti-EGFR therapy or
- 4mo agoVSTMVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic CancerBusiness Wire90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis 6-month overall survival rate was 86%; follow-up continues and survival data continue to mature Verastem Oncology (NASDAQ:VSTM),
- 4mo agoVSTMVerastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic CancerBusiness WireTARGET-D 201 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab for second-line treatment of metastatic pancreatic cancer A cohort in TARGET-D 201 will also evaluate the combination of
- 5mo agoVSTMVerastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerBusiness WirePhase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026 Phase 2
- 5mo agoVSTMVerastem Oncology to Present at Jefferies Healthcare ConferenceBusiness WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate
- 5mo agoVSTMVerastem Oncology Appoints Michael P. Bailey to its Board of DirectorsBusiness WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of
- 6mo agoVSTMVerastem Oncology to Present at Upcoming Investor ConferencesBusiness WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate
- 6mo agoVSTMOn World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian CancerBusiness WireAvailable at LGSOCAwarenessDay.Org, the LGSOC Resource Guide brings together resources from patient advocacy groups, covering topics from diagnosis to survivorship Today, STAAR Low-Grade Serous Ovarian Cancer
- 6mo agoVSTMVerastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesBusiness WireAVMAPKI® FAKZYNJA® CO-PACK net product revenue of $18.7 million Appointed Daniel Lyons as Chief Commercial Officer to lead next phase of commercial growth Initiated Phase 2 registration-directed trials
- 6mo agoVSTMVerastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian CancerBusiness WireLow-grade serous ovarian cancer (LGSOC) is a rare ovarian cancer with a high rate of recurrence affecting more than 80% of patients Integrated healthcare professional (HCP) and patient campaign features new websites
- 6mo agoVSTMVerastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026Business WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and
- 7mo agoVSTMVerastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's CancersBusiness WirePatients in the Phase 2 RAMP 201 clinical trial demonstrated sustained clinical benefits across multiple efficacy measures highlighting durability of response with a median follow-up of two years 52% of patients with
- 7mo agoVSTMVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 141,000 restricted stock units to eleven
- 7mo agoVSTMVerastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026Business WirePreclinical research with VS-7375 in combination with PRMT5 inhibitors demonstrated strong durable tumor regressions in KRAS G12D pancreatic cancer models In preclinical pancreatic, lung, and colorectal cancer models,
- 8mo agoVSTMVerastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's CancersBusiness WirePlenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trial Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to
- 8mo agoVSTMVerastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business UpdatesBusiness WireAVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025 Based on FDA
- 8mo agoVSTMVerastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026Business WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and
- 9mo agoVSTMVerastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven CancersBusiness WireBased on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million for
- 9mo agoONCYPFEVSTMCATX+1$668B Oncology Surge: 5 Platforms Cracking the Code on GI TumorsPR NewswireThe global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward gastrointestinal cancers...
- 10mo agoVSTMVerastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung CancerBusiness WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from the
- 11mo agoVSTMVerastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of GrowthBusiness WireJohn Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3
- 11mo agoVSTMVerastem Oncology to Present at the 8th Annual Evercore Healthcare ConferenceBusiness WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate
- 12mo agoVSTMVerastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its previously announced underwritten
- 12mo agoVSTMVerastem Oncology Announces Proposed Public Offering of Common StockBusiness WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell shares of its common
- 1y agoVSTMVerastem Oncology to Present at Upcoming Investor ConferencesBusiness WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate
- 1y agoVSTMVerastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business UpdatesBusiness WireAchieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $11.2 million VS-7375 cleared first two monotherapy dose levels with no dose-limiting toxicities reported; no nausea, vomiting or diarrhea
- 1y agoVSTMVerastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid TumorsBusiness WireFirst two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities reported Promising anti-tumor activity observed in patients with various solid tumors, including advanced
- 1y agoVSTMVerastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025Business WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and
- 1y agoVSTMVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 138,000 shares
- 1y agoVSTMVerastem Oncology to Present at Upcoming Investor ConferencesBusiness WireVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate
- 1y agoVSTMVerastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung CancerBusiness WireGFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the recommended Phase 2 dose of 600 mg QD GFH375 demonstrated an ORR of 57.7% in efficacy evaluable patients with
- 1y agoVSTMVerastem, Inc. (VSTM) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts